skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Tanibirumab (Code C102877)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Tanibirumab

Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression.

Label: Tanibirumab

NCI Thesaurus Code: C102877 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3490677  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
PDQ Closed Trial Search ID 738495
PDQ Open Trial Search ID 738495 (check for NCI PDQ open clinical trial info)
UMLS CUI C3490677

Other Properties:
     Name Value (qualifiers indented underneath)
code C102877
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom